TrialSignal
Clinical trial intelligence report
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT06847269-Jul 28, 2026
NCT ID
NCT06847269
Status
RECRUITING
Phase
PHASE2
Sponsor
St. Jude Children's Research Hospital
Executive brief
Investment-Ready Snapshot
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics is a PHASE2 clinical asset sponsored by St. Jude Children's Research Hospital in Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia. SEO and diligence focus: Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06847269
Indication
Acute Lymphoblastic Leukemia
Modality
small molecule
Target
Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion
Intervention
Fludarabine, Cyclophosphamide, Mesna, CD19-CAR T cell Infusion
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.